SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
__________
May 26, 1998
Date of Report (Date of earliest event reported)
AQUILA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
Delaware 0-12081 04-3307818
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification
incorporation) Number)
175 Crossing Boulevard
Framingham, Massachusetts 01702
(Address of principal executive offices and zip code)
(508) 628-0100
(Registrant's telephone number, including area code)
365 Plantation Street
Worcester, Massachusetts 01605
(Former name or former address, if changed since last report)
Item 5. Other Events.
On September 18, 1998, the Company's Board of Directors voted to amend
the Shareholder Rights Agreement by deleting the provisions relating to
"Continuing Directors."
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit 4.1. Amendment to Shareholder Rights Agreement,
dated as of September 18, 1998 (incorporated by reference to
Exhibit 1 to Form 8-A/A dated September 23, 1998, File No. 0-
12081).
AQUILA BIOPHARMACEUTICALS, INC.
/s/ Alison Taunton-Rigby
Date: September 23, 1998 By:__________________________________
Alison Taunton-Rigby, Chief Executive Officer
